Xeris Biopharma Holdings, Inc.
XERS · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Mar 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $292M | $203M | +43.7% |
| Operating income | $24.9M | −$33.6M | |
| Net income | $550K | −$54.8M |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 5, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $107M | $74.4M | +44.1% |
| Operating income | $16.9M | $6.70M | +152% |
| Net income | $11.3M | $600K | +1,783% |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was Xeris's revenue in FY2025?
- $292M in FY2025 (Fiscal year ended Dec 31, 2025), +43.7% vs $203M a year earlier, per its 10-K filed Mar 2026.
- Was Xeris profitable in FY2025?
- Yes: net income was $550K and operating income $24.9M in FY2025.
- What was Xeris's revenue in Q3 2026?
- $107M (+44.1% vs a year earlier), per its Form 10-Q filed Nov 5, 2026.